Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 20/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10297598 | 0.92 | GCK (0.59) | GCK | |
| SCHEMBL10297624 | 0.90 | GCK (0.56) | GCK | |
| SCHEMBL10297600 | 0.89 | GCK (0.64) | GCK | |
| SCHEMBL17573 | 0.87 | GCK (0.57) | GCK | |
| SCHEMBL16152074 | 0.87 | GCK (0.62) | GCK | |
| SCHEMBL3020008 | 0.87 | GCK (0.57) | GCK | |
| SCHEMBL24530 | 0.87 | GCK (0.57) | GCK | |
| SCHEMBL10297599 | 0.87 | GCK (0.56) | GCK | |
| SCHEMBL10297663 | 0.86 | GCK (0.58) | GCK | |
| Hydrochloric Acid SCHEMBL3014522 | 0.86 | GCK (0.57) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079890-B2 | Intermediates for the preparation of pyridin-2-yl-amino-1,2,4-thiadiazole derivatives | ARRAY BIOPHARMA INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20150057448-A1 | INTERMEDIATES FOR THE PREPARATION OF PYRIDIN-2-YL-AMINO-1,2,4-THIADIAZOLE DERIVATIVES | ARRAY BIOPHARMA, INC. | 2015-02-26 | — | — | US | disclosed |
| US-8853409-B2 | Pyridin-2yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus | ARRAY BIOPHARMA INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853409-B2 | Pyridin-2yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus | ARRAY BIOPHARMA INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20140155415-A1 | BENZODIOXEPINE AND BENZODIOXINE COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. | 2014-06-05 | — | — | US | disclosed |
| WO-2013123444-A1 | SULFONYL COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN | AMGEN INC. (US) | 2013-08-22 | — | — | WO | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120277242-A1 | Pyridin-2YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | ARRAY BIOPHARMA, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| WO-2012138776-A1 | BENZODIOXEPINE AND BENZODIOXINE COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-10-11 | — | — | WO | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-8212045-B2 | Pyridin-2-yl-amino-1, 2, 4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus | ARRAY BIOPHARMA, INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100204240-A1 | Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | ARRAY BIOPHARMA INC. (US) | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277242-A1 | Pyridin-2YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | PDXK, GCKR, GCK | GCK 3/4885 |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | GCKR, GCK, SLC5A2 | GCK 2/4885 |
| US-20150057448-A1 | INTERMEDIATES FOR THE PREPARATION OF PYRIDIN-2-YL-AMINO-1,2,4-THIADIAZOLE DERIVATIVES | PDXK, IL4I1, CDK2 | GCK 2487/4885 |
| US-20140155415-A1 | BENZODIOXEPINE AND BENZODIOXINE COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | GCKR, GCK, PDK2 | GCK 2/4885 |
| US-20100204240-A1 | Pyridin-2-YL-Amino-1, 2, 4-Thiadiazole Derivatives as Glucokinase Activators for the Treatment of Diabetes Mellitus | PDXK, GCKR, GCK | GCK 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.